"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
- Patient Information:
Details with Side Effects
Infasurf (calfactant) is indicated for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (“rescue”) of premature infants who develop RDS. Infasurf (calfactant) decreases the incidence of RDS, mortality due to RDS, and air leaks associated with RDS.
Prophylaxis therapy at birth with Infasurf (calfactant) is indicated for premature infants < 29 weeks of gestational age at significant risk for RDS. Infasurf (calfactant) prophylaxis should be administered as soon as possible, preferably within 30 minutes after birth.
DOSAGE AND ADMINISTRATION
FOR INTRATRACHEAL ADMINISTRATION ONLY
Infasurf (calfactant) should be administered under the supervision of clinicians experienced in the acute care of newborn infants with respiratory failure who require intubation.
Rapid and substantial increases in blood oxygenation and improved lung compliance often follow Infasurf (calfactant) instillation. Close clinical monitoring and surveillance following administration may be needed to adjust oxygen therapy and ventilator pressures appropriately.
Each dose of Infasurf (calfactant) is 3 mL/kg body weight at birth. Infasurf (calfactant) has been administered every 12 hours for a total of up to 3 doses.
Directions for Use
Infasurf (calfactant) is a suspension which settles during storage. Gentle swirling or agitation of the vial is often necessary for redispersion. DO NOT SHAKE. Visible flecks in the suspension and foaming at the surface are normal for Infasurf (calfactant) . Infasurf (calfactant) should be stored at refrigerated temperature 2° to 8°C (36° to 46°F). THE 3mL VIAL MUST BE STORED UPRIGHT. Date and time need to be recorded on the carton when Infasurf (calfactant) is removed from the refrigerator. Warming of Infasurf (calfactant) before administration is not necessary.
Unopened, unused vials of Infasurf (calfactant) that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Infasurf (calfactant) should not be removed from the refrigerator for more than 24 hours. Infasurf (calfactant) should not be returned to the refrigerator more than once. Repeated warming to room temperature should be avoided. Each single-use vial should be entered only once and the vial with any unused material should be discarded after the initial entry.
INFASURF (calfactant) DOES NOT REQUIRE RECONSTITUTION. DO NOT DILUTE OR SONICATE.
Infasurf (calfactant) should only be administered intratracheally through an endotracheal tube. The dose of Infasurf (calfactant) is 3 mL/kg birth weight. The dose is drawn into a syringe from the single-use vial using a 20-gauge or larger needle with care taken to avoid excessive foaming. Administration is made by instillation of the Infasurf (calfactant) suspension into the endotracheal tube.
Administration for Treatment of RDS
Infasurf (calfactant) should be administered intratracheally through a side-port adapter into the endotracheal tube. Two attendants, one to instill the Infasurf (calfactant) , the other to monitor the patient and assist in positioning, facilitate the dosing. The dose (3 mL/kg) should be administered in two aliquots of 1.5 mL/kg each. After each aliquot is instilled, the infant should be positioned with either the right or the left side dependent. Administration is made while ventilation is continued over 20-30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles. A pause followed by evaluation of the respiratory status and repositioning should separate the two aliquots.
Repeat doses of 3 mL/kg of birth weight, up to a total of 3 doses 12 hours apart, have been given in the Infasurf (calfactant) controlled clinical trials if the patient was still intubated.
In the Infasurf (calfactant) vs. Survanta® trials, Infasurf (calfactant) was administered through a 5 French feeding catheter inserted into the endotracheal tube. The total dose was instilled in four equal aliquots with the catheter removed between each of the instillations and mechanical ventilation resumed for 0.5 to 2 minutes. Each of the aliquots was administered with the patient in one of four different positions (prone, supine, right, and left lateral) to facilitate even distribution of the surfactant. Repeat doses were administered as early as 6 hours after the previous dose for a total of up to 4 doses if the infant was still intubated and required at least 30% inspired oxygen to maintain a PaO2 ≤ 80 torr.
Administration for Prophylaxis of RDS at Birth
The amount of a prophylaxis dose of Infasurf (calfactant) should be based on the infant's birth weight. Administration of Infasurf (calfactant) should be given as soon as possible after birth. Usually the immediate care and stabilization of the premature infant born with hypoxemia and/or bradycardia should precede Infasurf (calfactant) prophylaxis.
The dosing procedures are described under Administration for Treatment of RDS.
During administration of Infasurf (calfactant) liquid suspension into the airway, infants often experience bradycardia, reflux of Infasurf (calfactant) into the endotracheal tube, airway obstruction, cyanosis, dislodgement of the endotracheal tube, or hypoventilation. If any of these events occur, the administration should be interrupted and the infant's condition should be stabilized using appropriate interventions before the administration of Infasurf (calfactant) is resumed. Endotracheal suctioning or reintubation is sometimes needed when there are signs of airway obstruction during the administration of the surfactant.
Infasurf (calfactant) Intratracheal Suspension is supplied sterile in single-use, rubber-stoppered glass vials containing 3 mL (NDC 0456-4600-03) and 6 mL (NDC 0456-4600-06) off-white suspension.
Store Infasurf (calfactant) Intratracheal Suspension at refrigerated temperature 2° to 8°C (36° to 46°F) and protect from light. THE 3mL VIAL MUST BE STORED UPRIGHT. Vials are for single use only. After opening, discard unused drug.
Manufactured for: Forest Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc., St. Louis, MO 63045. by: ONY, Inc., Amherst, NY 14228. Rev. 06/03.
Last reviewed on RxList: 5/7/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Infasurf Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.